Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status:
Terminated
Trial end date:
2020-09-27
Target enrollment:
Participant gender:
Summary
This study is designed as a double-masked, randomized, placebo-controlled, clinical study to
evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in
participants with previous NAION. All participants enrolled in Cohort A of the study will
have a documented history of NAION for at least 12 months and at most, five years prior to
enrollment. Participants enrolled in Cohort B of the study will have a documented history of
NAION for at least 6 months and at most, three years prior to enrollment.